Cellectis SA (CLLS)

29.49
1.14 4.02
NASDAQ : Health Technology
Prev Close 28.35
Open 30.49
Day Low/High 29.23 / 30.49
52 Wk Low/High 21.25 / 38.85
Volume 284.68K
Avg Volume 145.80K
Exchange NASDAQ
Shares Outstanding 41.60M
Market Cap 1.21B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

FDA Grants Cellectis IND Approval For UCART22 In B-ALL

FDA Grants Cellectis IND Approval For UCART22 In B-ALL

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that the...

INSERTING And REPLACING: Approval Of UCART123 Amendment In AML to Accelerate Clinical Development

INSERTING And REPLACING: Approval Of UCART123 Amendment In AML to Accelerate Clinical Development

Regulatory News: This replaces the announcement made at 22:30 CEST on 22 May 2018 due to the following addendum: More information has been added to the first bullet point after the second paragraph Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a...

Cellectis: Approval Of UCART123 Amendment In AML to Accelerate Clinical Development

Cellectis: Approval Of UCART123 Amendment In AML to Accelerate Clinical Development

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the...

Calyxt Announces Launch Of Proposed Follow-On Offering

Calyxt Announces Launch Of Proposed Follow-On Offering

Regulatory News: Cellectis S.A.

Cellectis To Present Data At The 2018 ASGCT Annual Meeting

Cellectis To Present Data At The 2018 ASGCT Annual Meeting

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that...

Cellectis Reports 1st Quarter 2018 Financial Results

Cellectis Reports 1st Quarter 2018 Financial Results

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today its...

Cellectis Files IND For UCART22 In Acute Lymphoblastic Leukemia (B-ALL)

Cellectis Files IND For UCART22 In Acute Lymphoblastic Leukemia (B-ALL)

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that the...

Harvard's Wyss Institute Partners With Cellectis To Recode The Human Genome

Recode project will use Cellectis' TALEN gene editing technology to create first virus-resistant human cells for manufacturing therapeutics and developing new cell-based therapies

Harvard's Wyss Institute Partners With Cellectis To Recode The Human Genome

Harvard's Wyss Institute Partners With Cellectis To Recode The Human Genome

Regulatory News: Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing...

Cellectis Announces Pricing Of Follow-On Offering

Cellectis Announces Pricing Of Follow-On Offering

Regulatory News: Cellectis S.A.

Cellectis Announces Launch Of Follow-On Offering

Cellectis Announces Launch Of Follow-On Offering

Regulatory News: Cellectis S.A.

Cellectis And Allogene Therapeutics Intend To Continue Strategic Cancer Immunotherapy Collaboration To Accelerate Development And Commercialization Of Allogeneic Off-the-Shelf CAR T Therapies

Cellectis And Allogene Therapeutics Intend To Continue Strategic Cancer Immunotherapy Collaboration To Accelerate Development And Commercialization Of Allogeneic Off-the-Shelf CAR T Therapies

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic...

Dr. Mathieu Simon To Retire As Cellectis' Chief Operating Officer; Elsy Boglioli Named As Successor

Dr. Mathieu Simon To Retire As Cellectis' Chief Operating Officer; Elsy Boglioli Named As Successor

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited...

Cellectis Reports 4th Quarter And Full Year 2017 Financial Results

Cellectis Reports 4th Quarter And Full Year 2017 Financial Results

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited...

Cellectis: Servier And Pfizer Announce Results Of UCART19 First-in-Human Trials To Be Presented At The 44th EBMT (European Society For Blood And Marrow Transplantation) Annual Meeting

Cellectis: Servier And Pfizer Announce Results Of UCART19 First-in-Human Trials To Be Presented At The 44th EBMT (European Society For Blood And Marrow Transplantation) Annual Meeting

Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), today announced that results from the two phase 1 trials with UCART19, the...

Two Issued U.S. Patents Granted To Cellectis For CRISPR Use In T-Cells

Two Issued U.S. Patents Granted To Cellectis For CRISPR Use In T-Cells

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today...

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

Cellectis To Present At The 36th Annual J.P. Morgan Healthcare Conference On Monday, January 8, 2018 At 12:00 P.M. PT

Cellectis To Present At The 36th Annual J.P. Morgan Healthcare Conference On Monday, January 8, 2018 At 12:00 P.M. PT

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic...

Preliminary Data From Servier And Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult And Pediatric Acute Lymphoblastic Leukemia Trials

Preliminary Data From Servier And Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult And Pediatric Acute Lymphoblastic Leukemia Trials

Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS) presented at the 59th American Society of Hematology (ASH) Annual...

Cellectis Appoints Elsy Boglioli To Executive Vice President, Strategy And Corporate Development

Cellectis Appoints Elsy Boglioli To Executive Vice President, Strategy And Corporate Development

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR...

Cellectis Appoints Immuno-Oncology Leader Stéphane Depil To Position Of Senior Vice President Research & Development And Chief Medical Officer

Cellectis Appoints Immuno-Oncology Leader Stéphane Depil To Position Of Senior Vice President Research & Development And Chief Medical Officer

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR...

Cellectis Demonstrates Fine And Predictable Tuning Of TALEN® Gene Editing Targeting To Improve T-cell Adoptive Immunotherapy

Cellectis Demonstrates Fine And Predictable Tuning Of TALEN® Gene Editing Targeting To Improve T-cell Adoptive Immunotherapy

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic...

Cellectis Reports Financial Results For Third Quarter And First Nine Months Of 2017

Cellectis Reports Financial Results For Third Quarter And First Nine Months Of 2017

Regulatory News: Cellectis S.A.

FDA Lifts Clinical Hold On Cellectis Phase 1 Clinical Trials With UCART123 In AML And BPDCN

FDA Lifts Clinical Hold On Cellectis Phase 1 Clinical Trials With UCART123 In AML And BPDCN

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells...

First Week of December 15th Options Trading For Cellectis (CLLS)

First Week of December 15th Options Trading For Cellectis (CLLS)

Investors in Cellectis SA saw new options begin trading this week, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLLS options chain for the new December 15th contracts and identified one put and one call contract of particular interest.

Cellectis Announces Two Oral Presentations And One Poster Presentation At The 2017 ASH Annual Meeting

Cellectis Announces Two Oral Presentations And One Poster Presentation At The 2017 ASH Annual Meeting

Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR...

TheStreet Quant Rating: D (Sell)